Sector News

AstraZeneca to carve out antibiotic R&D into separate firm

February 27, 2015
Life sciences
(Reuters) – Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy areas.
 
Chief Executive Pascal Soriot said last year he was looking to partner or sell its anti-infective business, which is no longer viewed as a core area for the British drugmaker.
 
AstraZeneca said in an emailed statement it would invest $40 million in the new antibiotic company, which will include early-stage products such as a drug in Phase II for gonorrhoea. The move will impact approximately 95 employees based in Waltham, Massachusetts.
 
The new structure has no impact on anti-infective products already on the market, including Merrem, Zinforo, Fluenz/Flumist and Synagis. It also does not affect Avycaz, a new antibiotic approved this week from Actavis, which was co-developed with AstraZeneca.
 
Antibiotics have fallen out of favour in the past decade among many Big Pharma companies, because of their typically low margins. The industry has focused instead on more profitable areas, like cancer.
 
More recently some companies have started coming back to the space, given the demand for novel medicines that can fight drug-resistant superbugs, with Merck & Co agreeing to buy Cubist for $8.4 billion in December.
 
But AstraZeneca prefers to deploy its resources on its three priority areas of oncology; cardiovascular and metabolic diseases; and respiratory and inflammation.
 
The decision to carve-out early-stage antibiotics fits with Soriot’s aim of doing more so-called “externalisation”, involving the sale of non-core drugs, both to increase the company’s focus and generate additional income to see it through a tough period of patient expiries on older drugs.
 
Last year it struck a partnership deal worth up to $500 million for Alzheimer’s treatment with Eli Lilly, which could be a model for further transactions.
 
(Reporting by Ben Hirschler, editing by William Hardy)

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach